Published in Oncology (Williston Park) on June 01, 2009
Proposed definition of 'poor mobilizer' in lymphoma and multiple myeloma: an analytic hierarchy process by ad hoc working group Gruppo ItalianoTrapianto di Midollo Osseo. Bone Marrow Transplant (2011) 1.32
Over-expression of Thioredoxin-1 mediates growth, survival, and chemoresistance and is a druggable target in diffuse large B-cell lymphoma. Oncotarget (2012) 0.93
Metadherin interference inhibits proliferation and enhances chemo-sensitivity to doxorubicin in diffuse large B cell lymphoma. Int J Clin Exp Med (2014) 0.76
Relapsed/refractory diffuse large B-cell lymphoma: on the threshold of new therapies. Oncology (Williston Park) (2009) 0.75
Looking back (and ahead) at salvage treatment for non-Hodgkin lymphoma. Oncology (Williston Park) (2009) 0.75
Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study. J Clin Oncol (2006) 3.95
Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity. Lancet Oncol (2010) 3.76
Differential efficacy of bortezomib plus chemotherapy within molecular subtypes of diffuse large B-cell lymphoma. Blood (2009) 3.17
An enhanced International Prognostic Index (NCCN-IPI) for patients with diffuse large B-cell lymphoma treated in the rituximab era. Blood (2013) 2.65
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2010) 2.45
Treatment with ibritumomab tiuxetan radioimmunotherapy in patients with rituximab-refractory follicular non-Hodgkin's lymphoma. J Clin Oncol (2002) 2.41
Bendamustine is effective therapy in patients with rituximab-refractory, indolent B-cell non-Hodgkin lymphoma: results from a Multicenter Study. Cancer (2010) 2.19
Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model. Clin Cancer Res (2003) 2.09
Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo. Br J Haematol (2007) 2.05
Higher response to lenalidomide in relapsed/refractory diffuse large B-cell lymphoma in nongerminal center B-cell-like than in germinal center B-cell-like phenotype. Cancer (2011) 1.92
Tumor flare reaction associated with lenalidomide treatment in patients with chronic lymphocytic leukemia predicts clinical response. Cancer (2010) 1.90
Efficacy of lenalidomide in patients with chronic lymphocytic leukemia with high-risk cytogenetics. Leuk Lymphoma (2010) 1.78
Radioimmunotherapy of non-Hodgkin's lymphoma with 90Y-DOTA humanized anti-CD22 IgG (90Y-Epratuzumab): do tumor targeting and dosimetry predict therapeutic response? J Nucl Med (2003) 1.71
High rates of surveillance imaging for treated diffuse large B-cell lymphoma: findings from a large national database. Leuk Lymphoma (2012) 1.62
Ofatumumab in combination with ICE or DHAP chemotherapy in relapsed or refractory intermediate grade B-cell lymphoma. Blood (2013) 1.60
Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model. Clin Cancer Res (2005) 1.53
Safety, pharmacokinetics, and preliminary clinical activity of inotuzumab ozogamicin, a novel immunoconjugate for the treatment of B-cell non-Hodgkin's lymphoma: results of a phase I study. J Clin Oncol (2010) 1.38
Properties and structure-function relationships of veltuzumab (hA20), a humanized anti-CD20 monoclonal antibody. Blood (2008) 1.30
NCCN task force report: positron emission tomography (PET)/computed tomography (CT) scanning in cancer. J Natl Compr Canc Netw (2007) 1.26
Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol (2011) 1.26
A quantitative exploration of surface antigen expression in common B-cell malignancies using flow cytometry. Immunol Invest (2006) 1.20
Non-Hodgkin's lymphomas, version 1.2013. J Natl Compr Canc Netw (2013) 1.20
Non-Hodgkin's lymphomas, version 4.2014. J Natl Compr Canc Netw (2014) 1.17
Phase III randomized intergroup trial of CHOP plus rituximab compared with CHOP chemotherapy plus (131)iodine-tositumomab for previously untreated follicular non-Hodgkin lymphoma: SWOG S0016. J Clin Oncol (2012) 1.17
Acquired resistance to rituximab is associated with chemotherapy resistance resulting from decreased Bax and Bak expression. Clin Cancer Res (2008) 1.16
Comparison of referring and final pathology for patients with non-Hodgkin's lymphoma in the National Comprehensive Cancer Network. J Clin Oncol (2008) 1.15
Comparative outcome of initial therapy for younger patients with mantle cell lymphoma: an analysis from the NCCN NHL Database. Blood (2012) 1.08
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2011) 1.06
Distinct cellular and therapeutic effects of obatoclax in rituximab-sensitive and -resistant lymphomas. Br J Haematol (2011) 1.04
Non-Hodgkin's Lymphomas, version 3.2012. J Natl Compr Canc Netw (2012) 1.03
Lack of benefit of central nervous system prophylaxis for diffuse large B-cell lymphoma in the rituximab era: findings from a large national database. Cancer (2011) 0.97
Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20. Clin Cancer Res (2007) 0.95
Non-Hodgkin's lymphomas, version 2.2014. J Natl Compr Canc Netw (2014) 0.94
Therapy of advanced B-lymphoma xenografts with a combination of 90Y-anti-CD22 IgG (epratuzumab) and unlabeled anti-CD20 IgG (veltuzumab). Clin Cancer Res (2008) 0.93
Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab. Br J Haematol (2004) 0.90
Stem cell transplantation for follicular lymphoma relapsed/refractory after prior rituximab: a comprehensive analysis from the NCCN lymphoma outcomes project. Cancer (2013) 0.90
Regulation of CD20 in rituximab-resistant cell lines and B-cell non-Hodgkin lymphoma. Clin Cancer Res (2012) 0.89
Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model. Leuk Lymphoma (2005) 0.89
Regular use of aspirin or acetaminophen and risk of non-Hodgkin lymphoma. Cancer Causes Control (2005) 0.89
Dacetuzumab, a humanized mAb against CD40 for the treatment of hematological malignancies. Curr Opin Investig Drugs (2009) 0.88
Ofatumumab demonstrates activity against rituximab-sensitive and -resistant cell lines, lymphoma xenografts and primary tumour cells from patients with B-cell lymphoma. Br J Haematol (2011) 0.88
Prevention and management of cardiotoxicity from antineoplastic therapy. J Support Oncol (2004) 0.88
The novel proteasome inhibitor carfilzomib induces cell cycle arrest, apoptosis and potentiates the anti-tumour activity of chemotherapy in rituximab-resistant lymphoma. Br J Haematol (2013) 0.88
Bortezomib in combination with pegylated liposomal doxorubicin and thalidomide is an effective steroid independent salvage regimen for patients with relapsed or refractory multiple myeloma: results of a phase II clinical trial. Leuk Lymphoma (2009) 0.87
Long-term survival with allogeneic stem cell transplant and donor lymphocyte infusion following salvage therapy with anti-CD52 monoclonal antibody (Campath) in a patient with alpha/beta hepatosplenic T-cell non-Hodgkin's lymphoma. Leuk Lymphoma (2004) 0.87
(18)F-fluorodeoxyglucose-positron emission tomography/computed tomography after one cycle of chemotherapy in patients with diffuse large B-cell lymphoma: results of a Nordic/US intergroup study. Leuk Lymphoma (2014) 0.87
A comparative analysis of prognostic factor models for follicular lymphoma based on a phase III trial of CHOP-rituximab versus CHOP + 131iodine--tositumomab. Clin Cancer Res (2013) 0.86
Therapeutic options in relapsed or refractory diffuse large B-cell lymphoma. Part 1. current treatment approaches. Oncology (Williston Park) (2009) 0.84
Strategies to enhance rituximab anti-tumor activity in the treatment of CD20-positive B-cell neoplasms. Immunol Res (2010) 0.84
Distinct molecular mechanisms responsible for bortezomib-induced death of therapy-resistant versus -sensitive B-NHL cells. Blood (2010) 0.83
Radiation for diffuse large B-cell lymphoma in the rituximab era: analysis of the National Comprehensive Cancer Network lymphoma outcomes project. Cancer (2014) 0.82
Non-Hodgkin's lymphoma. Clinical practice guidelines in oncology. J Natl Compr Canc Netw (2006) 0.82
Antibody-drug conjugate technology development for hematologic disorders. Clin Adv Hematol Oncol (2012) 0.82
Entinostat, a novel histone deacetylase inhibitor is active in B-cell lymphoma and enhances the anti-tumour activity of rituximab and chemotherapy agents. Br J Haematol (2015) 0.82
Quality-of-life and health benefits of early treatment of mild anemia: a randomized trial of epoetin alfa in patients receiving chemotherapy for hematologic malignancies. Cancer (2006) 0.81
Novel approaches for the treatment of NHL: Proteasome inhibition and immune modulation. Leuk Lymphoma (2008) 0.81
Bendamustine for the treatment of indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Am J Health Syst Pharm (2010) 0.81
Transformed non-Hodgkin lymphoma in the rituximab era: analysis of the NCCN outcomes database. Br J Haematol (2013) 0.81
Chronic lymphocytic leukemia/small lymphocytic lymphoma, version 1.2015. J Natl Compr Canc Netw (2015) 0.81
The use of galiximab in non-Hodgkin lymphoma. Clin Lymphoma Myeloma (2008) 0.80
Single-agent lenalidomide is active in patients with relapsed or refractory aggressive non-Hodgkin lymphoma who received prior stem cell transplantation. Br J Haematol (2013) 0.80
Antilymphoma treatments given subsequent to Yttrium 90 ibritumomab tiuxetan are feasible in patients with progressive non-Hodgkin's lymphoma: a review of the literature. Clin Lymphoma (2004) 0.79
Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma. Clin Adv Hematol Oncol (2004) 0.79
NCCN task force report: molecular markers in leukemias and lymphomas. J Natl Compr Canc Netw (2009) 0.79
A steroid-independent regimen of bortezomib, liposomal doxorubicin and thalidomide demonstrate high response rates in newly diagnosed multiple myeloma patients. Br J Haematol (2011) 0.79
Galiximab: a review. Expert Opin Biol Ther (2010) 0.78
Comparison of referring and final pathology for patients with T-cell lymphoma in the National Comprehensive Cancer Network. Cancer (2014) 0.78
Non-Hodgkin's lymphomas. J Natl Compr Canc Netw (2008) 0.78
MLN2238, a proteasome inhibitor, induces caspase-dependent cell death, cell cycle arrest, and potentiates the cytotoxic activity of chemotherapy agents in rituximab-chemotherapy-sensitive or rituximab-chemotherapy-resistant B-cell lymphoma preclinical models. Anticancer Drugs (2013) 0.77
Update on novel monoclonal antibodies and immunoconjugates for the treatment of lymphoproliferative disorders. Future Oncol (2011) 0.77
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol (2002) 0.77
Ofatumumab: a novel, fully human anti-CD20 monoclonal antibody for the treatment of chronic lymphocytic leukemia. Future Oncol (2013) 0.76
Thrombotic microangiopathy after allogeneic blood and marrow transplantation is associated with dose-intensive myeloablative conditioning regimens, unrelated donor, and methylprednisolone T-cell depletion. Transplantation (2004) 0.76
Mitotic catastrophe and cell cycle arrest are alternative cell death pathways executed by bortezomib in rituximab resistant B-cell lymphoma cells. Oncotarget (2016) 0.75
Radioimmunotherapy in non-Hodgkin lymphoma. Curr Opin Oncol (2002) 0.75
Rituximab therapy for indolent non-Hodgkin's lymphoma. Anticancer Drugs (2002) 0.75
Clinical characteristics of gastrointestinal lymphomas associated with AIDS (GI-ARL) and the impact of HAART. HIV Clin Trials (2004) 0.75
Bcl-2 antisense therapy in B-cell malignant proliferative disorders. Curr Treat Options Oncol (2004) 0.75
Yttrium 90 ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory low-grade non-Hodgkin's lymphoma. Semin Oncol (2002) 0.75
Debate on the conservative and aggressive treatment options for the optimal management of indolent non-Hodgkin's lymphoma. Anticancer Drugs (2002) 0.75
Integrating emerging treatment options in mantle cell lymphoma. Clin Adv Hematol Oncol (2013) 0.75